Eris Lifesciences Ltd (ERIS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Eris Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
The Company will host "Eris Investor Meet - 2026" on November 19, 2026
Intimation · 29 Oct 2026, 10:51 pm
Eris Lifesciences Schedules Investor Meet on 19th Nov'26 Eris Lifesciences Limited announced that it will host the "Eris Investor Meet - 2026" on 19th Nov'26 in Mumbai. The interaction with company management will be conducted in a hybrid format (physical and virtual) for a group of institutional investors and analysts. The company confirmed that discussions will rely exclusively on publicly available information, with no unpublished price-sensitive information (UPSI) being shared.
as attached
Transcript · 29 Oct 2026, 10:47 pm
as attached
Audio / Video · 27 Oct 2026, 2:28 am
Eris Lifesciences Releases Q2 FY27 Earnings Call Audio Recording Eris Lifesciences has made available the audio recording of its earnings conference call held on 26th Oct'26. The call discussed the company's unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26 (Q2 FY27). Investors and analysts can access the complete recording directly via the investor relations section on the company's official website.
as attached
Investor Presentation · 26 Oct 2026, 7:25 pm
Eris Lifesciences Delivers Solid Q2 FY27 Results Driven by Core DBF Franchise Eris Lifesciences reported consolidated revenue growth of 12.6% YoY to Rs. 892 cr in Q2 FY27, with EBITDA rising 7.3% YoY to Rs. 309 cr (34.7% margin) and PAT surging 39.2% YoY to Rs. 187 cr (Adjusted PAT up 17.5% to Rs. 158 cr). Domestic Branded Formulations revenue climbed 14.1% YoY to Rs. 809 cr, driven by chronic therapies. In H1 FY27, ROCE expanded to 19% from 16% in FY26, alongside a net debt reduction of ~Rs. 111 cr.
as attached
Financial Result · 26 Oct 2026, 7:23 pm
as attached
Outcome · 26 Oct 2026, 7:19 pm
Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 26 Oct 2026, 7:19 pm
Eris Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 892 (+12.6% YoY | +2.2% QoQ) ■ EBITDA: 309 (+7.3% YoY | +4.4% QoQ) ■ EBITDA Margin (%): 34.7 (-171 bps YoY | +74 bps QoQ) ■ PAT: 184 (+52.9% YoY | +29.1% QoQ) ■ EPS (INR): 13.3 (+50.4% YoY | +29.1% QoQ)
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 26 Oct 2026, 5:30 am
As Attached
Intimation · 26 Oct 2026, 4:30 pm
Eris Lifesciences Schedules Q2 & H1 FY27 Earnings Call for 26th Oct'26 Eris Lifesciences Limited has scheduled an analyst and investor conference call on Monday, 26th Oct'26, at 04:30 PM IST. The management will discuss the company's standalone and consolidated unaudited financial results for the second quarter and half-year ended 30th Sep'26 (Q2 & H1 FY27). Pre-registration for the earnings call is accessible via Zoom.
As Attached
Intimation · 26 Oct 2026, 5:30 am
Eris Lifesciences Schedules Board Meeting for Q2 FY27 Financial Results Eris Lifesciences has scheduled a Board of Directors meeting on 26th Oct'26 to consider and approve its standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the company's trading window closed on 1st Oct'26 and will remain shut until 48 hours following the declaration of the financial results.
Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve Financial Results
Intimation · 26 Oct 2026, 5:30 am
Eris Lifesciences Schedules Board Meeting for Q2 FY27 Financial Results Eris Lifesciences Limited has scheduled a Board of Directors meeting on 26th Oct'26 to consider and approve its standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with SEBI Insider Trading Regulations, the company's trading window for designated persons has been closed since 1st Oct'26 and will remain shut until 48 hours post the official declaration of the financial results.
Eris Lifesciences Limited has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 26 Oct 2026, 5:30 am
As Attached
Change in Management · 05 Oct 2026, 5:33 pm
Eris Lifesciences Announces Resignation of Executive Director and COO Krishnakumar Vaidyanathan Eris Lifesciences Limited disclosed that Krishnakumar Vaidyanathan has resigned from his role as Executive Director and Chief Operating Officer (COO) to pursue external professional opportunities. His resignation became effective from the close of business hours on 30th Sep'26, following the company's acceptance along with a waiver of the notice period. The formal resignation letter was submitted to the exchanges on 5th Oct'26, following the initial intimation made on 11th Sep'26.
As Attached
Annual General Meeting · 26 Sept 2026, 1:04 am
Eris Lifesciences Shareholders Approve All Resolutions at 20th AGM Eris Lifesciences Limited announced the voting results of its 20th AGM held on 25th Sep'26, where shareholders approved all four proposed resolutions with requisite majorities. Key approvals include the adoption of audited standalone and consolidated financial statements for FY26 (100% in favor), the reappointment of Mr. Kaushal Kamlesh Shah as Director retiring by rotation (99.26% approval), the ratification of Cost Auditors' remuneration for FY27 (100% approval), and the reappointment of Mr. Sujesh Vasudevan as Independent Director via special resolution (97.67% approval). Total voter turnout reached ~88.24% of outstanding shares.
Proceedings of 20th AGM held on September 25 2026
Annual General Meeting · 25 Sept 2026, 5:33 pm
Proceedings of 29th Annual General Meeting of the Company held on 25th September 2026.
Annual General Meeting · 25 Sept 2026, 5:28 pm
As attached
Others (Uncategorized) · 22 Sept 2026, 10:19 pm
Eris Lifesciences Allots 1.55 Lakh Equity Shares Under ESOP Scheme Eris Lifesciences has allotted 1,55,264 equity shares of face value ₹1 each on 22nd Sep'26 pursuant to the exercise of stock options under its ESOP-2021 Scheme. The allotment includes 66,422 shares at ₹557.24 (2022 grant), 57,239 shares at ₹510.32 (2023 grant), and 31,603 shares at ₹728.16 (2024 grant). Consequently, the company's paid-up equity share capital increased from ₹13,85,83,305 (13,85,83,305 shares) to ₹13,87,38,569 comprising 13,87,38,569 equity shares.
as attached
Others (Uncategorized) · 21 Sept 2026, 2:41 pm
Eris Lifesciences Appoints Akhil Awasthi as Independent Director for Five-Year Term Eris Lifesciences approved the appointment of Mr. Akhil Awasthi as an Additional Director (Non-Executive, Independent) for a five-year term, effective 26th Sep'26, subject to shareholder approval. Mr. Awasthi brings over 30 years of experience across private equity, healthcare, lifesciences, and corporate governance. His background includes leadership roles as Founding Managing Partner at Tata Capital Growth Fund and Partner at Baring Private Equity Partners (India). He holds no familial ties to existing directors and faces no regulatory debarment from holding board positions.
As Attached
Change in Management · 11 Sept 2026, 9:42 pm
Eris Lifesciences Executive Director and COO Krishnakumar Vaidyanathan Resigns Eris Lifesciences Limited announced that Mr. Krishnakumar Vaidyanathan has resigned from his position as Executive Director & Chief Operating Officer (COO) to pursue external professional opportunities. The Chairman has accepted his resignation, and he will be formally relieved from his duties effective at the close of business hours on 30th Sep'26.
Eris Lifesciences Limited has informed the exchange about Rumor verification-Regulation 30 (11)
Others (Uncategorized) · 10 Sept 2026, 10:50 pm
Eris Lifesciences Clarifies Media Reports on Loan Details Eris Lifesciences issued a clarification on 10th Sep'26 regarding inaccurate news reports by publications including InvestyWise News and dealroom.co concerning its 9th Sep'26 disclosure. The company affirmed that the correct value of the loan availed is strictly as stated in its official regulatory filings submitted to stock exchanges, advising investors to rely exclusively on exchange-disseminated information for investment decisions.
As attached
Others (Uncategorized) · 09 Sept 2026, 10:57 pm
Eris Lifesciences Secures ₹45 Crore Term Loan from Axis Bank Eris Lifesciences executed a term loan agreement with Axis Bank on 9th Sep'26 to borrow ₹45 crore to meet other liabilities. The loan is secured by a charge on the company's brands. Total outstanding debt post-transaction stands at ₹155.77 crore in term loans and ₹55 crore in working capital loans. The company stated this is a routine financial adjustment and will not impact expected quarter-end net debt.
As Attached
Intimation · 07 Sept 2026, 5:55 pm
Eris Lifesciences Schedules Investor Meeting with Bank of India Mutual Fund Eris Lifesciences announced an upcoming 1x1 in-person meeting with Bank of India Mutual Fund, scheduled for 10th Sep'26 at 3:30 PM IST. Management will be represented by Krishnakumar Vaidyanathan. The company confirmed that discussions will rely exclusively on publicly available information, with no unpublished price-sensitive information (UPSI) to be shared.
as attached
Others (Uncategorized) · 03 Sept 2026, 12:37 am
as attached
Others (Uncategorized) · 03 Sept 2026, 12:32 am
as attached
Annual General Meeting · 03 Sept 2026, 12:26 am
Eris Lifesciences Announces 20th AGM and Key Board Re-appointments Eris Lifesciences will host its 20th AGM on 25th Sep'26 to adopt its audited FY26 financial statements. Key agenda items include the re-appointment of Executive Director Kaushal Kamlesh Shah, who received Rs 1.68 crore remuneration in FY26 and holds 4.46 million shares. Shareholders will also vote to re-appoint Sujesh Vasudevan as an Independent Director for a second five-year term spanning 25th Jul'27 to 24th Jul'32. Finally, the board seeks ratification of FY27 cost auditor remuneration set at Rs 3.66 lakh.